Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2008-04-08
2008-04-08
Li, Ruixiang (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C514S012200
Reexamination Certificate
active
11318156
ABSTRACT:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g., during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
REFERENCES:
patent: 5523227 (1996-06-01), Bram et al.
patent: 5541291 (1996-07-01), Keene
patent: 5650550 (1997-07-01), Korach et al.
patent: 5969102 (1999-10-01), Bram et al.
patent: 6316222 (2001-11-01), Bram et al.
patent: WO 95/35501 (1995-12-01), None
patent: WO 96/18641 (1996-06-01), None
patent: WO 98/39361 (1998-09-01), None
Wu, et al., Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J. Biol. Chem. 275:35478-35485, 2000.
Hymowitz et al., Structures of APRIL-receptor complexes. J. Biol. Chem. 280:7218-7227, 2005.
Bairoch, A., “The PROSITE Dictionary of Sites and Patterns in Proteins, Its Current Status,”Nucleic Acids Research, 1993, pp. 3097-3103, vol. 21, No. 13.
Bram, R.J., et al., “Identification of the Immunophilins Capable of Mediating Inhibition of Signal Transduction by Cyclosporin A and FK506: Roles of Calcineurin Binding and Cellular Location,”Molecular and Cellular Biology, Aug. 1993, pp. 4760-4769, vol. 13, No. 8.
Bram, R.J. and G.R. Crabtree, “Calcium Signalling in T Cells Stimulated by a Cyclophilin B-binding Protein,”Nature, Sep. 22, 1994, pp. 355-358, vol. 371.
Clipstone, N.A. and G.R. Crabtree, “Identification of Calcineurin as a Key Signalling Enzyme in T-lymphocyte Activation,”Nature, Jun. 25, 1992, pp. 695-697, vol. 357.
Crabtree, G.R. and N.A. Clipstone, “Signal Transmission Between the Plasma Membrane and Nucleus of T Lymphocytes,”Annu. Rev. Biochem., 1994, pp. 1045-1083, vol. 63.
Emmel, E.A., et al., “Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation,”Science, Dec. 22, 1989, pp. 1617-1620, vol. 246.
Fiering, S., et al., “Single Cell Assay of a Transcription Factor Reveals a Threshold in Transcription Activated by Signals Emanating from the T-cell Antigen Receptor,”Genes&Development, 1990, pp. 1823-1834, vol. 4.
Friedman, J. and I. Weissman, “Two Cytoplasmic Candidates for Immunophilin Action Are Revealed by Affinity for a New Cyclophilin: One in the Presence and One in the Absence of CsA,”Cell, Aug. 23, 1991, pp. 799-806, vol. 66.
Gao, X., et al., “Advanced Transgenic and Gene-Targeting Approaches,”Neurochemical Research, 1999, pp. 1181-1188, vol. 24, No. 9.
Gross, et al., “TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease,”Nature, 2000, pp. 995-999, vol. 404.
Gross, et al., “TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS,”Immunity, 2001, pp. 289-302, vol. 15.
Holloway, M.P. and R.J. Bram, “A Hydrophobic Domain of Ca2+-Modulating Cyclophilin Ligand Modulates Calcium Influx Signaling in T Lymphocytes,”Journal of Biological Chemistry, Apr. 12, 1996, pp. 8549-8552, vol. 271, No. 15.
Holloway, M.P. and R.J. Bram, “Co-localization of Calcium-modulating Cyclophilin Ligand with Intracellular Calcium Pools,”Journal of Biological Chemistry, Jun. 26, 1998, pp. 16346-16350, vol. 273, No. 26.
Hoth, M. and R. Penner, “Calcium Release-Activated Calcium Current in Rat Mast Cells,”Journal of Physiology, 1993, pp. 359-386, vol. 465.
Houdebine, L-M., “Transgenic Animal Bioreactors,”Transgenic Research, 2000, pp. 305-320, vol. 9.
Houdebine, L-M., “The Methods to Generate Transgenic Animals and to Control Transgene Expression,”Journal of Biotechnology, 2002, pp. 145-160, vol. 98.
Imboden, J.B., et al., “The Antigen Receptor on a Human T Cell Line Initiates Activation by Increasing Cytoplasmic Free Calcium,”Journal of Immunology, Feb. 1985, pp. 663-665, vol. 134, No. 2.
Karttunen, J. and N. Shastri, “Measurement of Ligand-induced Activation in Single Viable T Cells using thelacZReporter Gene,”Proc. Natl. Acad. Sci. USA, May 1991, pp. 3972-3976, vol. 88.
Kolb et al., “Insertion of a Foreign Gene Into the β-Casein Locus by Cre-Mediated Site-Specific Recombination,”Gene, 1999, pp. 21-31, vol. 227.
Leiter, E.H., “Mice with Targeted Gene Disruptions or Gene Insertions for Diabetes Research: Problems, Pitfalls, and Potential Solutions,”Diabetologia, 2002, pp. 296-308, vol. 45.
Liu, J. et al., “Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes,”Cell, Aug. 13, 1991, pp. 807-815, vol. 66.
O'Keefe, S.J., et al., “FK-506- and CsA-sensitive Activation of the Interleukin-2 Promoter by Calcineurin,”Nature, Jun. 25, 1992, pp. 692-694, vol. 357.
Premack, B.A., et al., “Activation of CA2+Current in Jurkat T Cells Following the Depletion of CA2+Stores by Microsomal CA2+-ATPase Inhibitors,”Journal of Immunology, 1994, pp. 5226-5240, vol. 152.
Putney, J.W., Jr., and G. St. J. Bird, The Signal for Capacitative Calcium Entry,Cell, Oct. 22, 1993, pp. 199-201, vol. 75.
Rudinger, J., “Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence,”Peptide Hormones, Jun. 1976, pp. 1-7, University Park Press, Baltimore.
Sigmund, C., “Viewpoint: Are Studies in Genetically Altered Mice Out of Control?,”Arterioscler. Thromb. Vasc. Biol., 2000, pp. 1425-1429.
Stryer, L., “Flow of Genetic Information,”BiochemistryFourth Edition, 1996, p. 111, W.H. Freeman and Company, New York.
Takebe, Y., et al., SRα Promoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of a Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat,Molecular and Cellular Biology, Jun. 1988, pp. 466-472, vol. 8, No. 1.
Tashiro, K. et al., “Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins,”Science, Jul. 30, 1993, pp. 600-603, vol. 261.
Truneh, A., et al., Early Steps of Lymphocyte Activation Bypassed by Synergy Between Calcium Ionophores and Phorbol Ester,Nature, Jan. 24, 1985, pp. 318-320, vol. 313.
Verweij, C.L., et al., “Cell Type Specificity and Activation Requirements for NFAT-1 (Nuclear Factor of Activated T-cells) Transcriptional Activity Determined by a New Method Using Transgenic Mice to Assay Transcriptional Activity of an Individual Nuclear Factor,”Journal of Biological Chemistry, Sep. 15, 1990, pp. 15788-15795. vol. 265, No. 26.
Von Bulow, G-U. and R.J. Bram, “NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily,”Science, Oct. 3, 1997, pp. 138-141, vol. 278.
Von Bulow, G-U. and R.J. Bram, “Activation of the Transcription Factor NFAT by a Novel CAML-interacting Member of the Tumor Necrosis Factor Receptor Superfamily,”Blood, Nov. 15, 1997, pp. 246A-247, vol. 90, No. 10, Suppl. 1, Part 1.
Von Bulow, G-U. et al., “Molecular Cloning and Functional Characterization of Murine Tr
Bram Richard J.
Von Bulow Gotz
Alston & Bird LLP
Li Ruixiang
St. Jude Children's Research Hospital
LandOfFree
Lymphocyte surface receptor that binds CAML and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lymphocyte surface receptor that binds CAML and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphocyte surface receptor that binds CAML and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3950082